Sitemap.
- Home.
-
Meet our lineup.
-
Open innovation.
- Disruptive solutions for liver care.
- Respiratory/nasal microbiota solutions for immune health.
- Disruptive solutions for liver and comorbidity management.
- Constipation selfcare empowerment.
- Nighttime pain relief.
- Next-Gen Natural Bioactive.
- Microbiome-based Solutions.
- Premium & Innovative Formats.
- Solutions for Effective Pain Relief.
- Biodegradable packaging solutions.
- Reliable & Actionable Diagnostics.
- Smart Packaging.
- Allergy Prevention, Diagnosis And Self Treatment.
- Constipation Selfcare Empowerment.
- Dual-action Constipation Relief.
- Treatment Of Abdominal Pain.
- Next-Gen Magnesium Solution.
- Solutions for Cough and Associated Pain Relief.
-
Open innovation.
- Meet Opella.
- Careers
-
Making Headlines.
- Biographies.
- Media gallery.
- Press kits.
-
Breaking news.
- Press Release: Opella launches as an independent company.
- Press Release: Sanofi and CD&R partner.
- Comunicado: Desabastecimento temporário dos medicamentos Bisolvon.
- Comunicado: Desabastecimento temporário dos medicamentos Bisolvon.
- Comunicado: Desabastecimento temporário dos medicamentos Mucosolvan.
- Comunicado: Desabastecimento temporário dos medicamentos Mucosolvan.
- Comunicado: Reativação de fabricação/importação do medicamento NOVALGINA®
- Comunicado: Reativação de fabricação/importação do medicamento ALLEGRA D®
- Press Release: Opella achieves global B Corp Certification.
- Communiqué de Presse: Opella Certifiée B Corp.
- Comunicado. Reativação de fabricação do medicamento Fenergan.
- Communiqué de Presse: Ségolène de Marsac nommée PDG d’Opella France.
- Comunicado: Reativação dos medicamentos Bisolvon
- Contact.
- Investors.
- Making an impact.
